Evaluating the Accuracy and Clinical Utility of AFIAS-10 Point of Care Versus Enzyme-Linked Immunosorbent Assay in Therapeutic Drug Monitoring of Infliximab and Adalimumab
The AFIAS-10 POC assay demonstrated good correlation and concordance with the ELISA method for the quantification of IFX and ADA, as well as for detecting anti-IFX and anti-ADA antibodies. However, this correlation was notably lower at higher drug concentrations.
Authors
- E. Martinez
- Carles Iniesta Navalón (ORCID: https://orcid.org/0000-0002-3950-7250)
- Lorena Rentero‐Redondo
- Elena Urbieta‐Sanz
- Rebeca Añez-Castaño
- Manuel Ríos‐Saorín
- Patricia Ortiz-Fernández
Institutions
- Hospital Universitario Reina Sofía (ES)
- Hospital Reina Sofía de Murcia (ES)
- Biomedical Research Institute (US)
- Universidad de Murcia (ES)
Publication Details
- Journal
- Therapeutic Drug Monitoring
- Published
- 2024-11-15
- DOI
- https://doi.org/10.1097/ftd.0000000000001269
- Citations
- 3
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 1.41